NCT03698370View on ClinicalTrials.gov

Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

February 11, 2022

Study Completion Date

February 11, 2022

Conditions
Prostate AdenocarcinomaPSA ProgressionRecurrent Prostate Carcinoma
Interventions
DRUG

Gallium Ga 68 DOTA-NeoBOMB1

Administered intravenously (IV)

DEVICE

Gallium Ga 68 PSMA-R2

Administered intravenously (IV)

Trial Locations (1)

94304

Stanford Cancer Institute Palo Alto, Palo Alto

All Listed Sponsors
lead

Andrei Iagaru

OTHER

NCT03698370 - Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter